Exelixis Inc Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31)
Exelixis Inc (EXEL) had Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) of $149.00 thousand as of 2013-03-31, per its 10-Q filed 2013-05-07.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1 · last filed 2013-05-07
- 2013-03-31: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) $149.00K.
- 2012-12-31: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) $191.00K.
- 2012-09-30: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) $103.00K.
- 2012-06-30: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) $57.00K.
| Period end | Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) |
|---|---|
| 2013-03-31 | $149.00K 10-Q · filed 2013-05-07 |
| 2012-12-31 | $191.00K 10-Q · filed 2013-05-07 |
| 2012-09-30 | $103.00K 10-Q · filed 2012-11-07 |
| 2012-06-30 | $57.00K 10-Q · filed 2012-08-02 |
| 2012-03-31 | $46.00K 10-Q · filed 2012-05-03 |
| 2011-12-31 | $173.00K 10-K · filed 2013-02-21 |
| 2010-12-31 | $11.00K 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |